Tuesday, November 17, 2026
HomeGadgetsStudy Reveals Genetic Clues Often Overlooked in Medication Prescriptions

Study Reveals Genetic Clues Often Overlooked in Medication Prescriptions

Your DNA might hold vital clues that your physician overlooks when prescribing medications.

A recent study released on Wednesday in Science Translational Medicine revealed that close to 25% of participants had been given medications that could have been better suited with an alternative drug or dosage based on their genetic information.

Conducted by a team from the University of Pittsburgh, the research focused on 16 specific genes that influence the body’s response to medications.

The analysis involved DNA samples from 98,590 participants in the National Institutes of Health’s All of Us Research Program, which were correlated with their medical histories when accessible.

All participants had at least one significant genetic variation that could influence their response to certain drugs, with an average participant possessing nine variations. Among those who had both genetic and clinical information, 24.4% had been prescribed at least one medication that, according to genetic guidelines, should have been switched for another or adjusted in dosage.

Nonetheless, the study did not ascertain whether patients faced adverse effects or if their treatment was less effective due to their genetic characteristics.

Dr. Philip Empey, the study’s senior author and an associate professor at the University of Pittsburgh’s School of Pharmacy, suggests that understanding a patient’s genetic makeup could lessen the trial-and-error approach in medicine.

“The more accurately we can predict the appropriate initial medications and their optimal dosages, the more we can minimize trial and error,” he noted.

A woman in a medical mask sorts pills on a counter.

A pharmacist arranges medications at a pharmacy in Vancouver in October 2022. Genetic variations can influence how patients respond to specific medications, possibly necessitating dosage adjustments or alternative prescriptions. (Darryl Dyck/The Canadian Press)

Identifying the Right Treatment

Among the most frequently prescribed medications for participants with genetic profiles that could warrant treatment alterations were omeprazole and pantoprazole for acid reflux, and atorvastatin for cholesterol management.

Empey pointed out that certain genetic variations may heighten the risk of muscular issues in patients taking statins like atorvastatin, which are utilized to mitigate the risk of heart attacks or strokes.

This information can guide physicians in selecting alternative medications or adjusting existing treatments.

“It empowers clinicians to make informed decisions, such as considering different cholesterol medications, starting with a lower dosage, or monitoring for specific side effects more closely,” Empey explained.

In some cases, the implications can be more severe.

For instance, specialists consulted by CBC News indicated that genetic testing can identify patients less likely to respond effectively to clopidogrel (Plavix), a medication prescribed to prevent blood clots post-cardiac stenting, allowing physicians to opt for alternative treatments.

A man in a suit and tie sits in a laboratory.

Dr. James Kennedy, head of the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health, emphasizes that while genetic testing can aid in medication selection, other factors like diet, lifestyle, and current medications must also be evaluated. (CBC)

A Guide, Not a Guarantee

Dr. James Kennedy, who heads the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health (CAMH), noted that the study’s findings were expected, though he was particularly impressed by the genetic diversity and representation of individuals of African descent.

Kennedy mentioned that his team has conducted genetic testing for around 11,000 patients, many of whom had unsuccessfully tried two or three different antidepressants.

He noted that approximately 8% to 10% of individuals metabolize certain commonly prescribed antidepressants at a significantly slower rate, leading to accumulation and possibly adverse effects.

Kennedy believes genetic testing is particularly beneficial for patients who have previously encountered challenges with multiple medications.

However, he cautioned that DNA testing alone cannot predict how a patient will react to specific medications. Other factors such as concurrent medications, smoking habits, and dietary choices must be taken into account.

“We provide a blueprint of your genetic tendencies, but we also need to consider all other factors before making a final decision,” he stated.

A 2023 European clinical trial referenced in the study indicated that genetic testing prior to prescribing certain drugs reduced adverse reactions. Nonetheless, integrating such testing into routine practice in Canada remains a challenge.

A person in purple gloves points to a small plastic test tube.

A researcher at the University of Calgary displays a diagnostic kit used for identifying genetic variations in February 2024. Although such testing could assist doctors in customizing medications for individual patients, the costs and practical challenges have hindered its widespread adoption in Canada. (Jeff McIntosh/The Canadian Press)

Challenges in Canada Regarding Widespread Testing

According to cardiologist Dr. Jacob Udell from Toronto, the study was commendable, especially considering the genetic diversity of its participants. However, he noted that very few healthcare providers in Canada or the U.S. routinely test for genetic variations that could impact medication metabolism.

“It’s definitely not something that frontline clinicians typically consider,” he remarked.

Udell pointed out that for many medical conditions, doctors can prescribe a medication, observe the patient’s reactions, and make necessary adjustments, usually without severe repercussions. This method can often be more pragmatic than conducting routine genetic screenings.

He also questioned the necessity of prioritizing widespread testing when Canada’s healthcare system is already struggling to provide fundamental services.

“We’re just trying to ensure everyone has access to a family doctor,” he stated.

Beyond the costs associated with testing, Udell emphasized that healthcare providers would need access to genetic test results and the expertise to interpret them accurately.

Empey concurred that establishing routine genetic testing would necessitate substantial investments in training, infrastructure, and new systems for sharing results among healthcare practitioners.

“The scientific basis for many medications is solid. The challenges of implementation are primarily economic, procedural, and educational,” he explained.

For the time being, Empey suggests that patients inquire with their doctors or pharmacists about the potential benefits of genetic testing and share any relevant results with them.

Udell cautioned that private genetic testing may become more prevalent among those who can afford it, “but this won’t assist those who cannot access such testing.”

Source

RELATED ARTICLES

Most Popular